This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

This disclosure relates to compositions and methods for recruiting brown adipocytes in vitro and in vivo from brown adipocyte progenitor cells found in human skeletal muscle. Methods for treating metabolic disease are also provided. Additionally, methods for treating hypothermia are provided. In some embodiments, the brown adipocyte recruiter is a human protein or peptide. In other embodiments the brown adipocyte recruiter may be a non-human protein or peptide. In still other embodiments, the brown adipocyte recruiter is a small molecule or natural product.

The present invention provides methods of treating the early stages of COVID-19 infection in a patient in need thereof. The methods comprise administering a therapeutically effective amount of a drug that increases signaling through the GC-A receptor, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. In certain aspects, the drug is a NEP inhibitor, a GC-A receptor agonist, or a pharmaceutically acceptable salt thereof. In certain embodiments, the methods of the present invention prevent the progression from the early stages of COVID-19 infection to hypoxemia, acute respiratory distress syndrome (ARDS) or death. In certain embodiments, the methods of the present invention prevent the development of pulmonary dysfunction after developing early symptoms of COVID-19 infection or the progression from mild to severe hypoxemia in these patients.

The present invention provides methods of treating the early stages of COVID-19 infection in a patient in need thereof. The methods comprise administering a therapeutically effective amount of a drug that increases signaling through the GC-A receptor, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. In certain aspects, the drug is a NEP inhibitor, a GC-A receptor agonist, or a pharmaceutically acceptable salt thereof. In certain embodiments, the methods of the present invention prevent the progression from the early stages of COVID-19 infection to hypoxemia, acute respiratory distress syndrome (ARDS) or death. In certain embodiments, the methods of the present invention prevent the development of pulmonary dysfunction after developing early symptoms of COVID-19 infection or the progression from mild to severe hypoxemia in these patients.

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.

In certain embodiments, the present invention provides a musclin peptide and methods of increasing muscle growth, performance, resistance to injury and/or preventing or reducing muscle atrophy and improving overall skeletal muscle, metabolic and cardiac health in an animal in need thereof by administering a musclin peptide.

This document provides methods and materials for preventing cytokine release syndrome (CRS). For example, methods and materials for using one or more catecholamine inhibitors to prevent a mammal from developing CRS are provided.

This document provides methods and materials for preventing cytokine release syndrome (CRS). For example, methods and materials for using one or more catecholamine inhibitors to prevent a mammal from developing CRS are provided.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.